US 12,479,832 B2
Liver targeting drug, pharmaceutical composition and use thereof
Jessica Xinyun Du, Redwood City, CA (US)
Assigned to Jessica Xinyun Du, Redwood City, CA (US); and Qiang Huang, Zhangjiagang (CN)
Appl. No. 17/772,264
Filed by Jessica Xinyun Du, Redwood City, CA (US); and Qiang Huang, Zhangjiagang (CN)
PCT Filed Nov. 2, 2020, PCT No. PCT/CN2020/125832
§ 371(c)(1), (2) Date Apr. 27, 2022,
PCT Pub. No. WO2021/088762, PCT Pub. Date May 14, 2021.
Claims priority of application No. 201911083040.6 (CN), filed on Nov. 7, 2019.
Prior Publication US 2022/0396566 A1, Dec. 15, 2022
Int. Cl. C07D 403/14 (2006.01); A61P 1/16 (2006.01)
CPC C07D 403/14 (2013.01) [A61P 1/16 (2018.01)] 7 Claims
 
1. A method for treating hepatitis B or liver cancer, comprising:
giving an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing one or more compounds of formula I, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, wherein the compound of formula I is

OG Complex Work Unit Chemistry
wherein:
R1 and R2 are each independently selected from: hydrogen or —COR′, where R1 and R2 are not hydrogen at the same time; and
R′ is selected from: hydrogen, or alkyl.